Editas Medicine, Inc.
NASDAQ:EDIT
3.59 (USD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 78.123 | 19.712 | 25.544 | 90.732 | 20.531 | 31.937 | 13.728 | 6.053 | 1.629 | 0 | 0 |
| Cost of Revenue
| 6.064 | 6.337 | 5.053 | 157.996 | 96.898 | 90.654 | 83.159 | 56.979 | 18.846 | 5.073 | 1.59 |
| Gross Profit
| 72.059 | 13.375 | 20.491 | -67.264 | -76.367 | -58.717 | -69.431 | -50.926 | -17.217 | -5.073 | -1.59 |
| Gross Profit Ratio
| 0.922 | 0.679 | 0.802 | -0.741 | -3.72 | -1.839 | -5.058 | -8.413 | -10.569 | 0 | 0 |
| Reseach & Development Expenses
| 171.587 | 174.958 | 142.507 | 157.996 | 96.898 | 90.654 | 83.159 | 56.979 | 18.846 | 5.073 | 1.59 |
| General & Administrative Expenses
| 69.653 | 70.704 | 76.183 | 67.576 | 64.555 | 55.01 | 50.502 | 46.262 | 18.095 | 7.65 | 3.63 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 69.653 | 70.704 | 76.183 | 67.576 | 64.555 | 55.01 | 50.502 | 46.262 | 18.095 | 7.65 | 3.63 |
| Other Expenses
| -1.604 | 1.293 | -1.698 | 16.259 | -0.137 | 0.328 | 0.587 | -0.057 | -37.445 | -0.928 | 0 |
| Operating Expenses
| 241.24 | 245.662 | 218.69 | 225.572 | 161.453 | 145.664 | 133.661 | 103.241 | 36.941 | 12.723 | 3.684 |
| Operating Income
| -169.181 | -225.95 | -193.146 | -134.84 | -140.922 | -113.727 | -119.933 | -97.188 | -35.312 | -12.723 | -5.22 |
| Operating Income Ratio
| -2.166 | -11.463 | -7.561 | -1.486 | -6.864 | -3.561 | -8.736 | -16.056 | -21.677 | 0 | 0 |
| Total Other Income Expenses Net
| 15.962 | 5.518 | 0.644 | 18.864 | 7.176 | 0.328 | 0.587 | -0.057 | -37.445 | -0.928 | -0.054 |
| Income Before Tax
| -153.219 | -220.432 | -192.502 | -115.976 | -133.746 | -109.954 | -120.324 | -97.183 | -72.9 | -13.685 | -5.274 |
| Income Before Tax Ratio
| -1.961 | -11.183 | -7.536 | -1.278 | -6.514 | -3.443 | -8.765 | -16.055 | -44.751 | 0 | 0 |
| Income Tax Expense
| 5.896 | -16.08 | -7.395 | -6.564 | -10.28 | -3.117 | -1.118 | -1.321 | -37.773 | -0.894 | 0.075 |
| Net Income
| -153.219 | -204.352 | -185.107 | -109.412 | -123.466 | -109.954 | -120.324 | -97.183 | -72.9 | -13.685 | -5.349 |
| Net Income Ratio
| -1.961 | -10.367 | -7.247 | -1.206 | -6.014 | -3.443 | -8.765 | -16.055 | -44.751 | 0 | 0 |
| EPS
| -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.8 |
| EPS Diluted
| -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.8 |
| EBITDA
| -163.117 | -225.95 | -193.146 | -134.84 | -141.059 | -113.399 | -119.346 | -97.245 | -72.757 | -13.494 | -5.217 |
| EBITDA Ratio
| -2.088 | -11.463 | -7.561 | -1.486 | -6.871 | -3.551 | -8.694 | -16.066 | -44.664 | 0 | 0 |